We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves MannKind’s Inhaled Afrezza to Treat Diabetes
FDA Approves MannKind’s Inhaled Afrezza to Treat Diabetes
The FDA on Friday approved Los Angeles-based MannKind Corp.’s rapid-acting inhaled insulin Afrezza Inhalation Powder to control blood sugar levels in adults with common type 2 diabetes during meals.